|
Marker
|
C-statistic (p value)
|
Nagelkerke’s R2
|
cNRI
|
Reclassification
|
|---|
|
Composite endpoint
|
|
Clinical model (CM)
|
0.815
|
0.645
| | |
|
CM + Stanniocalcin-2
|
0.821 (p = 0.100)
|
0.660
|
0.125 (− 0.053–0.363)
|
3.8% (0.9–6.9%)
|
|
CM + IGFBP-4
|
0.823 (p = 0.113)
|
0.671
|
0.270 (0.064–0.431)
|
5.0% (2.2–8.9%)
|
|
CM + Stanniocalcin-2 + IGFBP-4
|
0.826 (p = 0.036)
|
0.677
|
0.176 (0.001–0.420)
|
6.2% (3.1–9.6%)
|
|
All-cause mortality
|
|
Clinical model (CM)
|
0.807
|
0.636
| | |
|
CM + Stanniocalcin-2
|
0.808 (p = 0.555)
|
0.646
|
0.129 (− 0.129–0.330)
|
2.4% (0.3–4.8%)
|
|
CM + IGFBP-4
|
0.814 (p = 0.241)
|
0.662
|
0.248 (0.001–0.412)
|
3.7% (1.2–6.6%)
|
|
CM + Stanniocalcin-2 + IGFBP-4
|
0.814 (p = 0.204)
|
0.664
|
0.185 (− 0.041–0.433)
|
4.1% (1.6–7.0%)
|
|
Readmission due to heart failure
|
|
Clinical model (CM)
|
0.861
|
0.802
| | |
|
CM + Stanniocalcin-2
|
0.872 (p = 0.211)
|
0.825
|
0.256 (− 0.129–0.653)
|
1.31% (0.2–3.0%)
|
|
CM + IGFBP-4
|
0.861 (p = 0.103)
|
0.806
|
0.114 (− 0.285–0.446)
|
0.4% (0.0–1.9%)
|
|
CM + Stanniocalcin-2 + IGFBP-4
|
0.869 (p = 0.413)
|
0.823
|
0.239 (− 0.148–0.611)
|
1.6% (0.3–3.1%)
|
- Clinical model includes: age, sex, history of arterial hypertension, diabetes mellitus, heart failure, myocardial infarction, glomerular filtration rate and left ventricular ejection fraction
- IGFBP-4 insulin-like growth factor binding protein-4
